Alteogen and Daiichi Sankyo Partner to Develop and Commercialize SC Formulation of Enhertu
Shots:
- Alteogen has signed an exclusive license agreement with Daiichi Sankyo, as per which the latter secures global rights to ALT-B4 for the development & commercialization of SC formulation of Enhertu
- In exchange, Alteogen is eligible for an upfront, development, regulatory & sales milestones plus sales-based tiered royalties. It will also provide ALT-B4 to Daiichi Sankyo for clinical and commercial use
- ALT-B4 is a human recombinant hyaluronidase enzyme developed using Alteogen's Hybrozyme tech. It temporarily hydrolyzes hyaluronan in the extracellular matrix to facilitate the large-volume SC delivery of drugs, that are normally administered as IV
Ref: PR Newswire | Image: Daiichi Sankyo & Alteogen
Related News:- Daiichi Sankyo Reports the sNDA Submission of Enhertu to Treat HER2 Low or Ultralow Metastatic Breast Cancer in Japan
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
